Trading update: FY25 EBITDA marginally ahead
In a Trading Update for the year to 31st March 2025, Eco Animal Health reports that, due to strong trading in the final quarter, (adj.) EBITDA for the year is expected to be marginally ahead of expectations. FY25 revenue is expected to be c.7.0% below market expectations (-5% on a currency-adjusted basis), indicating revenue of c.£79.4m; the Group references market consensus FY25 (adj.) EBITDA of £7.2m (ED Est: £7.2m) and revenue of £85.3m (ED Est £84.2m). The improvement in EBITDA is driven by gross profitability above 45.0% (FY24: 42.1%) and control of overhead costs.Overall, the Group envisages that this level of gross profitability is sustainable (on a constant currency basis) and has made no changes to its outlook for FY26 and FY27. This is a validation of Group efforts to address operational processes and control costs in the face of what is described as “currency headwinds and geopolitical and economic uncertainty”.
Backed by the level of cash generation indicated, and as outlined in detail at the recent Group R&D Day (March 13th), Eco is committed to maintaining investment in the pipeline of major new products under development. We note the significance of the European Market Authorisation Application (MAA) for ECOVAXXIN®MS, Mycoplasma synoviae submitted on 3rd March (‘Milestone poultry vaccine submission’) as evidence of the defined pathway to commercialisation for the first of nine flagship products under development.
For reference, FY25 company (adj.) EBITDA guidance is in line with ED Est; our prior estimates are shown below. Our Fair Value remains 97p – 102p pending further review of the product pipeline detailed in the recent R&D Day.
Eco Animal Health Group is engaged in the manufacture and supply of animal health products. Co.'s activities were conducted through a network including both regional offices, (notably in Shanghai and Princeton) and overseas subsidiaries. Co.'s patented molecule, Aivlosin® is used for the treatment of pigs and poultry diseases and is prescribed under veterinary control for the short duration treatment of diagnosed diseases. Co.'s products also include Ecomectin, an endectocide that controls worms, ticks, lice and mange in grazing stock and pigs.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.